Research analysts at William Blair cut their Q1 2025 EPS estimates for Trupanion in a note issued to investors on Thursday, ...

Equities researchers at William Blair decreased their FY2025 earnings per share estimates for shares of Cheesecake Factory in ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

William Blair downgrades Booz Allen, CACI International, Leidos, Parsons and General Dynamics on the heightened risk of ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (WBAG:GEDY) from Outperform to Market Perform. There are 2,727 funds or institutions reporting ...

William Blair downgraded Booz Allen (BAH) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: See what ...

Pediatrix Medical reported Q4 revenue of $502.36 million, surpassing estimates, with adjusted EPS of $0.51. The company ...

William Blair analyst Dylan Becker upgraded Manhattan Associates (MANH) to Outperform from Market Perform without a price target The firm says ...

Repligen Corp (NASDAQ:RGEN) released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago ...